Three in Four FDA Authorizations of AI Medical Devices Were in Radiology
OVERVIEWA study led by GigHz founder documents that approximately 75% of FDA authorizations for AI medical devices concentrate in radiology, revealing significant specialty bias in AI device development and regulatory approval. This concentration reflects radiology's characteristics—high-volume imaging interpretation, well-defined diagnostic tasks, and abundant training data. The imbalance raises questions about AI development in other specialties and whether regulatory barriers, market incentives, or technical limitations explain the radiology dominance. Other high-potential AI applications in cardiology, oncology, and pathology lag significantly in FDA authorization. This specialty concentration may create a false impression that AI is only viable in imaging, potentially slowing development in other clinical domains where AI could add substantial value. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.